TY - JOUR
T1 - A deep multiple instance learning framework improves microsatellite instability detection from tumor next generation sequencing
AU - Ziegler, John
AU - Hechtman, Jaclyn F.
AU - Rana, Satshil
AU - Ptashkin, Ryan N.
AU - Jayakumaran, Gowtham
AU - Middha, Sumit
AU - Chavan, Shweta S.
AU - Vanderbilt, Chad
AU - DeLair, Deborah
AU - Casanova, Jacklyn
AU - Shia, Jinru
AU - DeGroat, Nicole
AU - Benayed, Ryma
AU - Ladanyi, Marc
AU - Berger, Michael F.
AU - Fuchs, Thomas J.
AU - Brannon, A. Rose
AU - Zehir, Ahmet
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2025/12
Y1 - 2025/12
N2 - Microsatellite instability (MSI) is a critical phenotype of cancer genomes and an FDA-recognized biomarker that can guide treatment with immune checkpoint inhibitors. Previous work has demonstrated that next-generation sequencing data can be used to identify samples with MSI-high phenotype. However, low tumor purity, as frequently observed in routine clinical samples, poses a challenge to the sensitivity of existing algorithms. To overcome this critical issue, we developed MiMSI, an MSI classifier based on deep neural networks and trained using a dataset that included low tumor purity MSI cases in a multiple instance learning framework. On a challenging yet representative set of cases, MiMSI showed higher sensitivity (0.895) and auROC (0.971) than MSISensor (sensitivity: 0.67; auROC: 0.907), an open-source software previously validated for clinical use at our institution using MSK-IMPACT large panel targeted NGS data. In a separate, prospective cohort, MiMSI confirmed that it outperforms MSISensor in low purity cases (P = 8.244e-07).
AB - Microsatellite instability (MSI) is a critical phenotype of cancer genomes and an FDA-recognized biomarker that can guide treatment with immune checkpoint inhibitors. Previous work has demonstrated that next-generation sequencing data can be used to identify samples with MSI-high phenotype. However, low tumor purity, as frequently observed in routine clinical samples, poses a challenge to the sensitivity of existing algorithms. To overcome this critical issue, we developed MiMSI, an MSI classifier based on deep neural networks and trained using a dataset that included low tumor purity MSI cases in a multiple instance learning framework. On a challenging yet representative set of cases, MiMSI showed higher sensitivity (0.895) and auROC (0.971) than MSISensor (sensitivity: 0.67; auROC: 0.907), an open-source software previously validated for clinical use at our institution using MSK-IMPACT large panel targeted NGS data. In a separate, prospective cohort, MiMSI confirmed that it outperforms MSISensor in low purity cases (P = 8.244e-07).
UR - http://www.scopus.com/inward/record.url?scp=85213972351&partnerID=8YFLogxK
U2 - 10.1038/s41467-024-54970-z
DO - 10.1038/s41467-024-54970-z
M3 - Article
AN - SCOPUS:85213972351
SN - 2041-1723
VL - 16
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 136
ER -